XT1061 / Xi’an XinTong Pharma - LARVOL DELTA

First-in-human study on the pharmacokinetics, safety, and tolerability of single escalating doses and multiple doses of XT1061, a novel core protein allosteric modulator, in healthy Chinese subjects. (PubMed, Front Pharmacol) - P1 | "These findings indicate that XT1061 possesses a favorable safety profile and predictable pharmacokinetics, providing a solid foundation for advancing into further clinical investigations to evaluate its efficacy and safety in patients with CHB. [http://www.chinadrugtrials.org.cn/index.html], identifier [CTR20232071]."

Clinical • First-in-human • Journal • P1 data • PK/PD data • Hepatitis B • Infectious Disease • Inflammation

Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd.

New P1 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation